Filgotinib, a JAK1 Inhibitor, Modulates Disease-Related Biomarkers in Rheumatoid Arthritis: Results from Two Randomized, Controlled Phase 2b Trials

ConclusionsFilgotinib regulates biomarkers from multiple pathways, indicative of direct and indirect network effects on the immune system and the stromal response. These effects were not associated with reductions of major circulating lymphoid populations.Trial RegistrationClinicalTrials.gov, NCT01888874, NCT01894516.
Source: Rheumatology and Therapy - Category: Rheumatology Source Type: research